South Korean biotech firm Celltrion’s distribution arm has signed provide offers for its monoclonal antibody to deal with COVID-19 with 9 European international locations, Celltrion Healthcare stated on Tuesday.
The European Fee earlier this month authorized the corporate’s antibody remedy, granting advertising and marketing authorisation for adults with COVID-19 who’re at elevated danger of progressing to a extreme situation.
The primary batch of fifty,000 doses shall be shipped to Europe this 12 months and the corporate is in talks with 47 different nations together with in Asia, Central and South America and the Center East, Celltrion stated in an announcement.
The antibody remedy was initially authorized in South Korea and has been administered to round 25,000 native COVID-19 sufferers as of final week.
Laboratory-made monoclonal antibodies mimic pure antibodies in combating off infections. In contrast to vaccines, they don’t depend on the physique to create an immune response, and may due to this fact assist people with weak or compromised immune methods.
(Reuters)